Drug combo ups progression-free survival for metastatic prostate cancer (talazoparib plus enzalutamide)

Medical Xpress / HealthDay / The Lancet ^ | June 8, 2023 | Elana Gotkine / Wassim Abida et al / Neeraj Agarwal et al

[ConservativeMind]

For patients with metastatic castration-resistant prostate cancer (mCRPC), talazoparib plus enzalutamide results in improvement in radiographic progression-free survival (rPFS), according to a study.

Neeraj Agarwal, M.D. and colleagues conducted a randomized phase 3 trial of talazoparib plus enzalutamide versus placebo plus enzalutamide as first-line therapy for men with asymptomatic or mildly symptomatic mCRPC receiving ongoing androgen deprivation therapy from 223 hospitals, cancer centers, and medical centers in 26 countries. Patients were prospectively assessed for homologous recombination repair gene alterations in tumor tissue and randomly assigned to once daily talazoparib or placebo (402 and 203 patients, respectively).

The researchers found that the median rPFS was not reached for talazoparib plus enzalutamide and was 21.9 months for placebo plus enzalutamide at the planned primary analysis (hazard ratio, 0.63). The most common treatment-emergent adverse events were anemia, neutropenia, and fatigue in the talazoparib group; anemia was the most common grade 3 to 4 event (46 percent of patients), which improved after dose reduction and resulted in discontinuation in 8 percent of patients. No patients in the talazoparib group and two in the placebo group (<1 percent) had treatment-related deaths.

"Results from the primary analysis of the all-comers population of the TALAPRO-2 trial support the consideration of talazoparib plus enzalutamide as a first-line treatment option in patients with mCRPC," the authors write.

[ConservativeMind]

The median response was not reached, so people could do much better on this therapy than these results show.

[webheart]

Someone who posts every single article from a medical website on a political forum hopefully is donating to the people who created and have maintained the site with no advertising whatsoever.

[Robert357]

Bump for reference

[Mariner]

“talazoparib”

A hard chemo therapy drug that can make any remaining life miserable.

But such is the fate of us with metastatic cancer.

[beef]

We talk about news here, and it is not all politics. I for one like to hear about medical advances that could benefit me.

[ConservativeMind]

I very likely give more to Free Republic than you do, troll.

I do not work for Medical Xpress and get nothing from that site.

What profession do you come from and how did you make your money?

[Jacquerie]

<>I for one like to hear about medical advances that could benefit me.<>

Ditto.

At the very end of the article instead of near the beginning:

<>Several authors disclosed ties to pharmaceutical companies, including Pfizer, which manufactures talazoparib and enzalutamide and funded the study.<>

Thanks to the book below, I've become a far better consumer of medicine and doctor's opinions.

Dr. John Abramson was featured in a recent Hillsdale Imprimus.